Search results
Results from the WOW.Com Content Network
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity. A fundamental philosophy of medical oncology , including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Description of the list of classifications Archived 2013-07-28 at the Wayback Machine, IARC. List of Classifications (latest version) List of classifications by cancer site Archived 2012-09-20 at the Wayback Machine (last updated on 5 November 2015)
Description of the list of classifications Archived 2013-07-28 at the Wayback Machine, IARC. List of Classifications (latest version) List of Classifications by cancer sites with sufficient or limited evidence in humans, Volumes 1 to 124 (Last update: 8 July 2019) Agents Classified by the IARC Monographs, Volumes 1–123 (Last update: 25 March ...
Almost all patients treated with ABVD receive less than this dose (for 6 cycles of ABVD, the cumulative adriamycin dose is 300 mg/m 2); therefore, adriamycin-related cardiac toxicity is very uncommon with ABVD. Secondary malignancies. Patients cured of Hodgkin lymphoma remain at increased risk of developing other (secondary) cancers.
This list is focusing on the hazard linked to the agents. This means that the carcinogenic agents are capable of causing cancer, but this does not take their risk into account, which is the probability of causing a cancer given the level of exposure to this carcinogenic agent. [2] The list is uptodate as of January 2024. [3]